Laboratory Corp. of America (NYSE: LH) was downgraded by equities researchers at Goldman Sachs from a “neutral” rating to a “sell” rating in a report issued on Monday. They currently have a $83.00 target price on the stock.
Shares of Laboratory Corp. of America opened at 82.40 on Monday. Laboratory Corp. of America has a 52 week low of $79.01 and a 52 week high of $95.30. The company has a market cap of $7.795 billion and a P/E ratio of 13.58.
Laboratory Corp. of America last announced its earnings results on Thursday, October 18th. The company reported $1.76 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.74 by $0.02. Laboratory Corp. of America’s revenue was up 1.1% compared to the same quarter last year. Analysts expect that Laboratory Corp. of America will post $6.91 EPS for the current fiscal year.
Other equities research analysts have also recently issued reports about the stock. Analysts at WallachBeth upgraded shares of Laboratory Corp. of America from a “hold” rating to a “buy” rating in a research note to investors on Tuesday, November 13th. They now have a $97.00 price target on the stock, up previously from $91.00. Separately, analysts at Jefferies Group reiterated a “hold” rating on shares of Laboratory Corp. of America in a research note to investors on Tuesday, October 23rd. They now have a $90.00 price target on the stock. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Laboratory Corp. of America in a research note to investors on Friday, October 19th. They now have a $93.00 price target on the stock.
Laboratory Corporation of America Holdings is a clinical laboratory company. As of December 31, 2011, it had a national network of 54 primary laboratories and over 1,700 patient service centers (PSCs) along with a network of branches and STAT laboratories (which are laboratories that have the ability to perform certain routine tests quickly and report the results to the physician immediately).
Shares of Laboratory Corp. of America opened at 82.40 on Monday. Laboratory Corp. of America has a 52 week low of $79.01 and a 52 week high of $95.30. The company has a market cap of $7.795 billion and a P/E ratio of 13.58.
Laboratory Corp. of America last announced its earnings results on Thursday, October 18th. The company reported $1.76 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.74 by $0.02. Laboratory Corp. of America’s revenue was up 1.1% compared to the same quarter last year. Analysts expect that Laboratory Corp. of America will post $6.91 EPS for the current fiscal year.
Other equities research analysts have also recently issued reports about the stock. Analysts at WallachBeth upgraded shares of Laboratory Corp. of America from a “hold” rating to a “buy” rating in a research note to investors on Tuesday, November 13th. They now have a $97.00 price target on the stock, up previously from $91.00. Separately, analysts at Jefferies Group reiterated a “hold” rating on shares of Laboratory Corp. of America in a research note to investors on Tuesday, October 23rd. They now have a $90.00 price target on the stock. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Laboratory Corp. of America in a research note to investors on Friday, October 19th. They now have a $93.00 price target on the stock.
Laboratory Corporation of America Holdings is a clinical laboratory company. As of December 31, 2011, it had a national network of 54 primary laboratories and over 1,700 patient service centers (PSCs) along with a network of branches and STAT laboratories (which are laboratories that have the ability to perform certain routine tests quickly and report the results to the physician immediately).